STAT+: Judge bars Shkreli from running another public company, fines him $1.4 million
A U.S. District Court judge has granted a request from the U.S. Securities and Exchange…
Category: drug pricing
STAT+: Chilean health ministry is urged to issue a compulsory license for the Pfizer Covid pill
In the latest bid to expand access to the Pfizer (PFE) Covid-19 pill, a nonprofit…
STAT+: ‘It’s almost negligible’: More top hospitals aren’t offering controversial Alzheimer’s drug Aduhelm
WASHINGTON — Almost no one is prescribing Aduhelm, the controversial new Alzheimer’s treatment that roiled…
STAT+: Drug makers ring in the new year with 5% price hikes on hundreds of medicines
As 2022 gets under way, pharmaceutical companies have so far raised wholesale prices by a…
STAT+: HHS appeals rulings over drug discount program just as AbbVie is latest to cut discounts
A heated clash over a U.S. government drug discount program has intensified after a federal…
Opinion: Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices?
Astellas Pharma, a drug company headquartered in Japan, is charging U.S. patients $156,000 a year…
STAT+: 3 pharma trends to watch in 2022
As 2021 winds down, the proverbial rearview mirror displays a mix of spectacular success, vexing…
Opinion: Why the big questions about drug prices are rarely asked: It’s hard to do
Public debate over legislation to allow Medicare to negotiate the price of drugs has been…
STAT+: Generic drug makers win a court round as judge temporarily blocks California pay-to-delay law
In a victory for generic drug makers, a federal court judge temporarily blocked a controversial California…
.jpg)
STAT+: Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug
Six years after a national scandal erupted, a group of federal and state authorities have…
STAT+: Centene agrees to pay $28 million to resolve another state probe into its PBM business
Centene (CNC), one of the largest health insurers in the U.S., agreed to pay nearly…
STAT+: As Biden touts his effort to cap insulin prices, advocates push for an even more ambitious reform
WASHINGTON — President Biden promised Monday that Democrats’ signature drug pricing plan will mean no…
Opinion: Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing
The Senate began its confirmation hearing last week for President Biden’s nominee to head the…
STAT+: Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals
Amid a closely watched legal battle, Amgen (AMGN) has joined the growing ranks of major…
STAT+: Socially responsible investor coalitions push greater access to medicines in shareholder proposals
Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor…
What does the Build Back Better Act actually mean for the health care industry?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Democrats’ major drug pricing reforms clear a hurdle in the House
WASHINGTON — House Democrats Friday broke a monthslong logjam and advanced prescription drug pricing reform…
STAT+: Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass
A controversial proposal for the World Trade Organization to temporarily waive intellectual property rights and…
Moderate Democrats are still seeking changes to the party’s drug pricing package
WASHINGTON — Rep. Kurt Schrader, the Oregon Democrat who has played an outsized role in…
STAT+: ‘Can’t get much worse:’ What a European rejection of an Alzheimer’s drug would mean for Biogen
In a potentially huge setback for Biogen (BIIB), a European regulatory panel signaled that it…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020
During 2020, drug makers raised prices on seven widely used medicines by substantial amounts without…
STAT+: Like Merck, Pfizer strikes a licensing deal with the Medicines Patent Pool for a Covid-19 pill
Amid considerable anticipation over its Covid-19 pill, Pfizer (PFE) reached a licensing agreement with the…
STAT+: Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B
The high cost of the Alzheimer’s drug from Biogen (BIIB) is a key reason that…
Opinion: Drug pricing bill’s unintended consequences will distort drug development
After months of wrangling, Democratic lawmakers have agreed on a drug pricing bill. The House…
STAT+: STAT+ Conversation: Drug pricing drama
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
How Nancy Pelosi almost killed drug pricing reform
WASHINGTON — The White House stunned health care experts last month when it declared it was…
STAT+: Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs
Nearly a dozen of the highest-rated hospitals in the U.S. charged commercial health insurers and…
Opinion: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars
Americans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs. But the…
Listen: Moderna’s setback, the saga of drug pricing reform & a CEO’s next act
Is drug pricing reform actually happening? Why was Moderna’s stock down? And what’s next for…
Here’s who wins and loses in Democrats’ new prescription drug pricing deal
WASHINGTON — Congressional Democrats on Tuesday announced they had agreed to a broad plan to overhaul…
Democrats circulate a new drug pricing outline with a big carveout for small biotechs
WASHINGTON — A proposed version of drug pricing legislation circulating among Capitol Hill aides and…
Here’s where Democrats’ resurrected drug pricing talks are headed
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: With two new insurance partnerships, EQRx takes its first steps toward lowering drug prices. But how big are those steps?
EQRx — the buzzy biotech company with a lofty mission of making far less expensive…
STAT+: Government’s bid to force drug makers to offer discounts to some hospitals was ‘arbitrary and capricious,’ judge rules
After more than a year of controversy, a federal court judge ruled the U.S. government…
STAT+: Pharmalittle: Pelosi tries last-ditch drug pricing proposal; Merck sees up to $7B in Covid pill sales in 2022
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Here’s how Biden can address high drug prices, without help from Congress
WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve…
Pelosi working to gather support for last-minute, last-ditch drug pricing policy
WASHINGTON — House Speaker Nancy Pelosi’s office is working to gather support for a last-ditch…
STAT+: Biden abandons his push to lower drug prices
WASHINGTON — The White House is abandoning every single policy idea aimed at lowering prescription…
Which drug maker spent the most on lobbying this summer? The answer will surprise you
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: ‘For good rather than evil’: Mark Cuban and an employer’s coalition to launch new PBMs to lower drug costs
As Americans grapple with prescription drug costs, two new companies are being launched in hopes…
STAT+: The four senators who could make or break Democrats’ drug pricing ambitions
WASHINGTON — The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate…
STAT+: Pharmalittle: Power for Medicare to negotiate drug prices grows less likely; FDA OKs mix-and-match Covid booster shots
Top of the morning to you. And a fine one it is. Crystal clear blue…
STAT+: Takeda strikes a rebate deal for lung cancer drug as health plans look to value-based agreements
In another bid to address the cost of prescription medicines, Takeda Pharmaceuticals (TAK) and 32PointHealth…
STAT+: Pharmalittle: WHO hopes to buy Covid treatments for $10 a course; Sinema is a big obstacle to drug pricing reform
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs
Phoenix, Ariz. is no Kendall Square. Its biotech companies, ventures like OncoMyx Therapeutics and VisionGate,…
STAT+: FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious
For the first time, U.S. regulators have approved an interchangeable, biosimilar version of Humira, a…
STAT+: Pfizer will use a warranty to refund the cost of a lung cancer drug if it doesn’t work
In an unusual bid to address prescription drug costs, Pfizer (PFE) is promising to offer…
Opinion: Much Adu(helm) about nothing: New Alzheimer’s drug threatens state Medicaid budgets
A new drug that was supposed to be a lifeline for thousands of individuals and…
Opinion: Biosimilars competition helps patients more than generic competition
Much of the current drug-pricing agenda proposed by President Biden and by Congress is based…
Opinion: A federal drug purchasing program could save billions
When Amazon, Berkshire Hathaway, and JPMorgan announced they were creating a new health care company…